Molecular biology reports · 2025
The role of visfatin and omentin-1 gene polymorphism in pancreatic ductal adenocarcinoma (PDAC).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Badr Eman Ae, Salem Waheed M, Mekhail Yostena, Rashed Hager Mohamed
Аннотация
BACKGROUND: Pancreatic ductal adenocarcinoma is a highly aggressive digestive system tumor with a poor prognosis. It is characterized by aggressive features and non-specific early symptoms, often leading to detection only after metastasis has occurred.
OBJECTIVES: To investigate the role of visfatin rs4730153 and omentin-1 rs2274907 gene polymorphisms in susceptibility to pancreatic cancer, while evaluating their serum levels and correlating these levels with clinical, laboratory, and pathological data.
SUBJECTS AND METHODS: This study involved 192 participants, including 96 native pancreatic cancer patients with confirmed histopathological examinations and 96 age- and gender-matched controls. All individuals underwent a comprehensive medical history assessment, physical examination, and ultrasound imaging. Serum levels of visfatin, omentin-1, and tumor markers were measured using ELISA techniques. Genotyping of visfatin (rs4730153) and omentin (rs2274907) polymorphisms was conducted using quantitative fluorescent PCR.
RESULTS: The GG genotype and G allele of rs4730153 were significantly more prevalent in the patient group, with odds ratios of 4.154 and 1.711, respectively. Additionally, vascular invasion, poor survival, and a progressive disease course were significantly more common in the AG and GG genotypes. The distribution of omentin-1 rs2274907 indicated that higher serum visfatin levels, larger tumor sizes, vascular invasion, metastasis, poor survival, and lower serum omentin-1 levels were significantly more prevalent in the AT and TT genotypes.
CONCLUSION: The visfatin rs4730153 gene polymorphism is associated with susceptibility to pancreatic cancer, vascular invasion, a progressive disease course, and poor survival outcomes. In contrast, the omentin-1 rs2274907 polymorphism is linked to tumor size, vascular invasion, metastasis, and overall survival.
OBJECTIVES: To investigate the role of visfatin rs4730153 and omentin-1 rs2274907 gene polymorphisms in susceptibility to pancreatic cancer, while evaluating their serum levels and correlating these levels with clinical, laboratory, and pathological data.
SUBJECTS AND METHODS: This study involved 192 participants, including 96 native pancreatic cancer patients with confirmed histopathological examinations and 96 age- and gender-matched controls. All individuals underwent a comprehensive medical history assessment, physical examination, and ultrasound imaging. Serum levels of visfatin, omentin-1, and tumor markers were measured using ELISA techniques. Genotyping of visfatin (rs4730153) and omentin (rs2274907) polymorphisms was conducted using quantitative fluorescent PCR.
RESULTS: The GG genotype and G allele of rs4730153 were significantly more prevalent in the patient group, with odds ratios of 4.154 and 1.711, respectively. Additionally, vascular invasion, poor survival, and a progressive disease course were significantly more common in the AG and GG genotypes. The distribution of omentin-1 rs2274907 indicated that higher serum visfatin levels, larger tumor sizes, vascular invasion, metastasis, poor survival, and lower serum omentin-1 levels were significantly more prevalent in the AT and TT genotypes.
CONCLUSION: The visfatin rs4730153 gene polymorphism is associated with susceptibility to pancreatic cancer, vascular invasion, a progressive disease course, and poor survival outcomes. In contrast, the omentin-1 rs2274907 polymorphism is linked to tumor size, vascular invasion, metastasis, and overall survival.